These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
422 related articles for article (PubMed ID: 26002965)
1. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Hagner PR; Man HW; Fontanillo C; Wang M; Couto S; Breider M; Bjorklund C; Havens CG; Lu G; Rychak E; Raymon H; Narla RK; Barnes L; Khambatta G; Chiu H; Kosek J; Kang J; Amantangelo MD; Waldman M; Lopez-Girona A; Cai T; Pourdehnad M; Trotter M; Daniel TO; Schafer PH; Klippel A; Thakurta A; Chopra R; Gandhi AK Blood; 2015 Aug; 126(6):779-89. PubMed ID: 26002965 [TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678 [TBL] [Abstract][Full Text] [Related]
3. Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB. Solomon LA; Batista CR; DeKoter RP Exp Hematol; 2017 Dec; 56():46-57.e1. PubMed ID: 28893618 [TBL] [Abstract][Full Text] [Related]
5. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516 [TBL] [Abstract][Full Text] [Related]
6. Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL. Hagner PR; Chiu H; Chopra VS; Colombo M; Patel N; Estevez MO; Waldman MF; Loos R; Towfic F; Gandhi AK Clin Cancer Res; 2022 Aug; 28(15):3367-3377. PubMed ID: 35583604 [TBL] [Abstract][Full Text] [Related]
7. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Lu G; Middleton RE; Sun H; Naniong M; Ott CJ; Mitsiades CS; Wong KK; Bradner JE; Kaelin WG Science; 2014 Jan; 343(6168):305-9. PubMed ID: 24292623 [TBL] [Abstract][Full Text] [Related]
8. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos. Matyskiela ME; Zhang W; Man HW; Muller G; Khambatta G; Baculi F; Hickman M; LeBrun L; Pagarigan B; Carmel G; Lu CC; Lu G; Riley M; Satoh Y; Schafer P; Daniel TO; Carmichael J; Cathers BE; Chamberlain PP J Med Chem; 2018 Jan; 61(2):535-542. PubMed ID: 28425720 [TBL] [Abstract][Full Text] [Related]
9. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Yang Y; Shaffer AL; Emre NC; Ceribelli M; Zhang M; Wright G; Xiao W; Powell J; Platig J; Kohlhammer H; Young RM; Zhao H; Yang Y; Xu W; Buggy JJ; Balasubramanian S; Mathews LA; Shinn P; Guha R; Ferrer M; Thomas C; Waldmann TA; Staudt LM Cancer Cell; 2012 Jun; 21(6):723-37. PubMed ID: 22698399 [TBL] [Abstract][Full Text] [Related]
10. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725 [TBL] [Abstract][Full Text] [Related]
11. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Sievers QL; Petzold G; Bunker RD; Renneville A; Słabicki M; Liddicoat BJ; Abdulrahman W; Mikkelsen T; Ebert BL; Thomä NH Science; 2018 Nov; 362(6414):. PubMed ID: 30385546 [TBL] [Abstract][Full Text] [Related]
12. Protein Degradation via CRL4 Hansen JD; Condroski K; Correa M; Muller G; Man HW; Ruchelman A; Zhang W; Vocanson F; Crea T; Liu W; Lu G; Baculi F; LeBrun L; Mahmoudi A; Carmel G; Hickman M; Lu CC J Med Chem; 2018 Jan; 61(2):492-503. PubMed ID: 28358507 [TBL] [Abstract][Full Text] [Related]
13. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Van Wier S; Chang XB; Bjorklund CC; Fonseca R; Bergsagel PL; Orlowski RZ; Stewart AK Blood; 2011 Nov; 118(18):4771-9. PubMed ID: 21860026 [TBL] [Abstract][Full Text] [Related]
14. The molecular mechanism of thalidomide analogs in hematologic malignancies. Lindner S; Krönke J J Mol Med (Berl); 2016 Dec; 94(12):1327-1334. PubMed ID: 27492707 [TBL] [Abstract][Full Text] [Related]
15. UBE2G1 governs the destruction of cereblon neomorphic substrates. Lu G; Weng S; Matyskiela M; Zheng X; Fang W; Wood S; Surka C; Mizukoshi R; Lu CC; Mendy D; Jang IS; Wang K; Marella M; Couto S; Cathers B; Carmichael J; Chamberlain P; Rolfe M Elife; 2018 Sep; 7():. PubMed ID: 30234487 [TBL] [Abstract][Full Text] [Related]
16. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201 [TBL] [Abstract][Full Text] [Related]
17. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase. Petzold G; Fischer ES; Thomä NH Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574 [TBL] [Abstract][Full Text] [Related]
18. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574 [TBL] [Abstract][Full Text] [Related]
19. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Matyskiela ME; Lu G; Ito T; Pagarigan B; Lu CC; Miller K; Fang W; Wang NY; Nguyen D; Houston J; Carmel G; Tran T; Riley M; Nosaka L; Lander GC; Gaidarova S; Xu S; Ruchelman AL; Handa H; Carmichael J; Daniel TO; Cathers BE; Lopez-Girona A; Chamberlain PP Nature; 2016 Jul; 535(7611):252-7. PubMed ID: 27338790 [TBL] [Abstract][Full Text] [Related]
20. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]